AR081197A1 - Lactamas sustituidas con piperidinil o como moduladores de gpr 119 - Google Patents
Lactamas sustituidas con piperidinil o como moduladores de gpr 119Info
- Publication number
- AR081197A1 AR081197A1 ARP110101683A ARP110101683A AR081197A1 AR 081197 A1 AR081197 A1 AR 081197A1 AR P110101683 A ARP110101683 A AR P110101683A AR P110101683 A ARP110101683 A AR P110101683A AR 081197 A1 AR081197 A1 AR 081197A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- alkoxy
- halogen
- methyl
- Prior art date
Links
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- -1 (cyclopropylmethyl) sulfonyl Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000006594 (C1-C3) alkylsulfony group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 abstract 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 1
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 206010012655 Diabetic complications Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 102100033839 Glucose-dependent insulinotropic receptor Human genes 0.000 abstract 1
- 101000996752 Homo sapiens Glucose-dependent insulinotropic receptor Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 125000001715 oxadiazolyl group Chemical group 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 125000001425 triazolyl group Chemical group 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Son moduladores de GPR119 y son útiles en el tratamiento o la prevención de enfermedades tales como, en forma no taxativa, diabetes tipo 2, complicaciones diabéticas, síntomas de la diabetes, síndrome metabólico, obesidad, dislipidemia y condiciones relacionadas. Reivindicación 1: Un compuesto caracterizado porque tiene la fórmula general (1 ) o una sal farmacéuticamente aceptable o un solvato de él, en donde L es O o NRx; Rx es H o alquilo C1-3; X1 es N o CR1 y X2 es N o CR2, en donde solamente uno de X1 y X2 puede ser N; R1, R2, R3 y R4 se seleccionan independientemente de H, halógeno, CF3, alquilo C1-6 y alcoxi C1-6; R5 es alquilo C1-3sulfonilo, cicloalquilo C3-6 sulfonilo, (ciclopropilmetil)sulfonilo, fenilsulfonilo, CN, Br, CF3, triazolilo, alcoxi C1-4carbonilo, RxRyNHC(=O)-, oxadiazolilo opcionalmente sustituido con alquilo C1-3, y tetrazolilo opcionalmente sustituido con alquilo C1-3; o cuando X1 es CR1 y X2 es CR2, entonces R4 y R5 opcionalmente junto con los átomos a los cuales están unidos forman un anillo heterocíclico saturado de 5-6 miembros que tiene 1-2 heteroátomos del anillo seleccionados independientemente de O y S y opcionalmente sustituidos con un grupo oxo, en donde el S cuando está presente está opcionalmente oxidado; Rx y Ry son independientemente alquilo C1-4) opcionalmente sustituido con OH, o Rx y Ry junto con el átomo al cual están unidos forman un anillo azacíclico saturado de 5-6 miembros opcionalmente sustituidos con OH; R6 es H, OH o metilo; R6a es H o metilo; R7 es un grupo que tiene la estructura de fórmulas (2); A1 es N o CRa; A2 es N o CRb; A3 es N o CRc; A4 es N o CRd, en donde por lo menos uno de A1, A2, A3 y A4 es N, y no más de dos de A1, A2, A3 y A4 pueden ser N; Ra, Rb, Rc y Rd son independientemente H, CF3, halógeno, alquilo C1-4 o CN; R8 se selecciona de hidrógeno, halógeno CF3, CN, alquilo C1-10, hidroxialquilo C1-6, alcoxi C1-6, alquilo C1-6sulfanilo, fenilo, piridilo, pirimidilo, pirazolilo, y dialquilo C1-3carbamilo, en donde cada uno de dichos fenilo, piridilo, pirimidilo, y pirazolilo se sustituye opcionalmente con uno o más sustituyentes seleccionados independientemente de alquilo C1-4, alcoxi C1-4 y CF3; R9 y R9a son independientemente hidrógeno o metilo; y n es 1, 2 o 3.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34546110P | 2010-05-17 | 2010-05-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR081197A1 true AR081197A1 (es) | 2012-07-04 |
Family
ID=44584599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110101683A AR081197A1 (es) | 2010-05-17 | 2011-05-17 | Lactamas sustituidas con piperidinil o como moduladores de gpr 119 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8754226B2 (es) |
| EP (1) | EP2571864A1 (es) |
| JP (1) | JP2013530947A (es) |
| KR (1) | KR20130113948A (es) |
| CN (1) | CN103080101A (es) |
| AR (1) | AR081197A1 (es) |
| AU (1) | AU2011256455A1 (es) |
| BR (1) | BR112012029395A2 (es) |
| CA (1) | CA2799779A1 (es) |
| CL (1) | CL2012003211A1 (es) |
| CO (1) | CO6670520A2 (es) |
| CR (1) | CR20120642A (es) |
| IL (1) | IL223092A0 (es) |
| MX (1) | MX2012013465A (es) |
| RU (1) | RU2012154308A (es) |
| SG (1) | SG185615A1 (es) |
| TW (1) | TW201141849A (es) |
| UY (1) | UY33392A (es) |
| WO (1) | WO2011146335A1 (es) |
| ZA (1) | ZA201209605B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8754226B2 (en) | 2010-05-17 | 2014-06-17 | Array Biopharma Inc. | Piperidinyl-substituted lactams as GPR119 modulators |
| EP2718279B1 (en) | 2011-06-09 | 2016-08-10 | Rhizen Pharmaceuticals SA | Novel compounds as modulators of gpr-119 |
| KR101415742B1 (ko) * | 2011-12-21 | 2014-07-04 | 영남대학교 산학협력단 | 6―아미노피리딘―3―올 유도체 또는 이의 약제학적 허용가능한 염 및 이를 유효성분으로 함유하는 혈관신생으로 인한 질환의 예방 또는 치료용 약학조성물 |
| EP2872127A1 (en) | 2012-07-11 | 2015-05-20 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| US9499482B2 (en) | 2012-09-05 | 2016-11-22 | Bristol-Myers Squibb Company | Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists |
| AR092924A1 (es) | 2012-10-09 | 2015-05-06 | Sanofi Sa | Derivados de pirrolidinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados |
| CN105431435A (zh) * | 2013-06-07 | 2016-03-23 | 拜耳制药股份公司 | 具有作为mps-1抑制剂的活性的取代的三唑并吡啶类 |
| AR099936A1 (es) * | 2014-04-04 | 2016-08-31 | Sanofi Sa | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados |
| AR099937A1 (es) | 2014-04-04 | 2016-08-31 | Sanofi Sa | Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados |
| RU2016143092A (ru) * | 2014-04-04 | 2018-05-08 | Санофи | Замещенные соединения инданона в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных с ними нарушений |
| JP6649279B2 (ja) | 2015-01-19 | 2020-02-19 | 株式会社フジミインコーポレーテッド | 変性コロイダルシリカおよびその製造方法、並びにこれを用いた研磨剤 |
| TWI763621B (zh) * | 2015-01-19 | 2022-05-11 | 日商福吉米股份有限公司 | 研磨用組成物之製造方法 |
| EP3390399A1 (en) | 2015-12-17 | 2018-10-24 | Syngenta Participations AG | Microbiocidal oxadiazole derivatives |
| EP3585775B1 (en) | 2017-02-21 | 2022-04-06 | Sanofi | Azetidine compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders |
| EP4153589A1 (en) | 2020-05-19 | 2023-03-29 | Kallyope, Inc. | Ampk activators |
| JP2023531020A (ja) | 2020-06-22 | 2023-07-20 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | スルホン誘導体 |
| CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
| CN114539073A (zh) * | 2022-02-18 | 2022-05-27 | 郑州萃智医药科技有限公司 | 3-溴-2-氯-4,6-二氟苯胺的合成方法 |
| WO2024033374A1 (en) | 2022-08-11 | 2024-02-15 | Syngenta Crop Protection Ag | Novel arylcarboxamide or arylthioamide compounds |
| WO2024089216A1 (en) | 2022-10-27 | 2024-05-02 | Syngenta Crop Protection Ag | Novel sulfur-containing heteroaryl carboxamide compounds |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6710058B2 (en) | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
| WO2005061489A1 (en) | 2003-12-24 | 2005-07-07 | Prosidion Limited | Heterocyclic derivatives as gpcr receptor agonists |
| EP1732885A1 (en) | 2004-02-23 | 2006-12-20 | Trustees Of Tufts College | Lactams as conformationally constrained peptidomimetic inhibitors |
| TW200610761A (en) | 2004-04-23 | 2006-04-01 | Astrazeneca Ab | Chemical compounds |
| CN1997640A (zh) | 2004-06-04 | 2007-07-11 | 艾尼纳制药公司 | 作为代谢调节剂的经取代芳基和杂芳基衍生物及其相关病症的预防和治疗 |
| EP1817302A4 (en) * | 2004-11-22 | 2009-07-01 | Merck & Co Inc | PIPERIDINYLPIPERIDIN-tachykinin receptor Antagonist |
| US7423043B2 (en) * | 2005-02-18 | 2008-09-09 | Lexicon Pharmaceuticals, Inc. | 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds |
| US20090264650A1 (en) * | 2005-03-31 | 2009-10-22 | Nobuo Cho | Prophylactic/Therapeutic Agent for Diabetes |
| TW200724139A (en) | 2005-05-05 | 2007-07-01 | Warner Lambert Co | Androgen modulators |
| US20090203676A1 (en) | 2005-06-30 | 2009-08-13 | Oscar Barba | G-protein Coupled Receptor Agonists |
| US20100063081A1 (en) | 2005-06-30 | 2010-03-11 | Stuart Edward Bradly | CPCR Agonists |
| US20080025795A1 (en) * | 2006-07-28 | 2008-01-31 | Cliff Purnell | Methods, apparatus and system for drain tiles |
| US20080103123A1 (en) * | 2006-08-30 | 2008-05-01 | Biovitrum | New compounds |
| JP2010513488A (ja) | 2006-12-20 | 2010-04-30 | メルク・シャープ・エンド・ドーム・コーポレイション | ビピペリジニル化合物、その化合物を含有する組成物及び治療方法 |
| AU2008279447A1 (en) | 2007-07-19 | 2009-01-29 | Metabolex, Inc. | N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders |
| US20110230507A1 (en) | 2008-07-10 | 2011-09-22 | Prosidion Limited | Piperidine GPCR Agonists |
| TW201006821A (en) | 2008-07-16 | 2010-02-16 | Bristol Myers Squibb Co | Pyridone and pyridazone analogues as GPR119 modulators |
| CN107011330B (zh) * | 2009-09-04 | 2020-07-03 | 比奥根Ma公司 | 布鲁顿酪氨酸激酶抑制剂 |
| CN102918027A (zh) | 2010-04-06 | 2013-02-06 | 艾尼纳制药公司 | Gpr119受体调节剂和对与所述受体有关的障碍的治疗 |
| US8754226B2 (en) | 2010-05-17 | 2014-06-17 | Array Biopharma Inc. | Piperidinyl-substituted lactams as GPR119 modulators |
| RU2013117403A (ru) | 2010-09-17 | 2014-10-27 | Эррэй Биофарма Инк. | Пиперидинил-замещенные лактамы как модуляторы gpr119 |
| WO2013066869A1 (en) | 2011-11-03 | 2013-05-10 | Array Biopharma Inc. | Piperidinyl-substituted lactams as gpr119 modulators |
| US20140309226A1 (en) | 2011-11-16 | 2014-10-16 | Array Biopharma Inc. | Piperidinyl-substituted cyclic ureas as gpr119 modulators |
-
2011
- 2011-05-13 US US13/698,257 patent/US8754226B2/en not_active Expired - Fee Related
- 2011-05-13 JP JP2013511238A patent/JP2013530947A/ja not_active Withdrawn
- 2011-05-13 WO PCT/US2011/036443 patent/WO2011146335A1/en active Application Filing
- 2011-05-13 CN CN2011800291586A patent/CN103080101A/zh active Pending
- 2011-05-13 AU AU2011256455A patent/AU2011256455A1/en not_active Abandoned
- 2011-05-13 KR KR1020127032867A patent/KR20130113948A/ko not_active Application Discontinuation
- 2011-05-13 EP EP11754769A patent/EP2571864A1/en not_active Withdrawn
- 2011-05-13 BR BR112012029395A patent/BR112012029395A2/pt not_active IP Right Cessation
- 2011-05-13 MX MX2012013465A patent/MX2012013465A/es not_active Application Discontinuation
- 2011-05-13 SG SG2012084471A patent/SG185615A1/en unknown
- 2011-05-13 CA CA2799779A patent/CA2799779A1/en not_active Abandoned
- 2011-05-13 RU RU2012154308/04A patent/RU2012154308A/ru not_active Application Discontinuation
- 2011-05-17 UY UY0001033392A patent/UY33392A/es not_active Application Discontinuation
- 2011-05-17 AR ARP110101683A patent/AR081197A1/es unknown
- 2011-05-17 TW TW100117276A patent/TW201141849A/zh unknown
-
2012
- 2012-11-16 CL CL2012003211A patent/CL2012003211A1/es unknown
- 2012-11-18 IL IL223092A patent/IL223092A0/en unknown
- 2012-12-17 CO CO12228271A patent/CO6670520A2/es not_active Application Discontinuation
- 2012-12-17 CR CR20120642A patent/CR20120642A/es unknown
- 2012-12-18 ZA ZA2012/09605A patent/ZA201209605B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2571864A1 (en) | 2013-03-27 |
| RU2012154308A (ru) | 2014-06-27 |
| US20130158009A1 (en) | 2013-06-20 |
| WO2011146335A1 (en) | 2011-11-24 |
| US8754226B2 (en) | 2014-06-17 |
| CL2012003211A1 (es) | 2013-04-26 |
| AU2011256455A1 (en) | 2013-01-10 |
| MX2012013465A (es) | 2013-12-02 |
| TW201141849A (en) | 2011-12-01 |
| CA2799779A1 (en) | 2011-11-24 |
| ZA201209605B (en) | 2014-05-28 |
| BR112012029395A2 (pt) | 2016-07-26 |
| IL223092A0 (en) | 2013-02-03 |
| SG185615A1 (en) | 2012-12-28 |
| KR20130113948A (ko) | 2013-10-16 |
| UY33392A (es) | 2012-11-30 |
| CO6670520A2 (es) | 2013-05-15 |
| CN103080101A (zh) | 2013-05-01 |
| CR20120642A (es) | 2013-03-11 |
| JP2013530947A (ja) | 2013-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR081197A1 (es) | Lactamas sustituidas con piperidinil o como moduladores de gpr 119 | |
| AR083003A1 (es) | Lactamas sustituidas por piperidinilo como moduladores de gpr119 | |
| AR081369A1 (es) | Compuestos de 2-5-6-7-tetrahidro-(1,4) oxazepin-3-ilamina o 2,3,6,7-tetrahidro-(1,4) oxazepin-5-ilamina, sus procesos de obtencion y composiciones farmaceuticas que los contienen | |
| AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
| AR092270A1 (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR082446A1 (es) | N-((6-amino-piridin-3-il)-metil)-heteroaril-carboxamidas | |
| PE20141211A1 (es) | Moduladores receptores de hormonas nucleares | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| AR091781A1 (es) | Antagonistas del receptor de 5-ht3 | |
| AR085316A1 (es) | Derivados de pirrolo[2,3-b]piridina, utiles para la modulacion de quinasas | |
| AR094911A1 (es) | SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO ASÍ COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARÍNICO M₃ | |
| IN2014MN01897A (es) | ||
| PE20160839A1 (es) | Derivados de 4-azaindol | |
| ES2531274T3 (es) | Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas | |
| ECSP13012980A (es) | Derivados de fenil- o piridinil-etinilo | |
| AR081960A1 (es) | Compuestos heterociclicos, su preparacion y su aplicacion terapeutica | |
| DOP2014000287A (es) | Compuestos de fenoxietil piperidina | |
| CO6351734A2 (es) | Compuestos de amida utiles en terapia | |
| JP2010155827A5 (es) | ||
| BR112015005186A2 (pt) | 2-oxo-2,3-di-hidro-indóis para tratamento de distúrbios do snc | |
| AR085398A1 (es) | Ureas asimetricas y usos medicos de las mismas | |
| AR087274A1 (es) | Derivados de amidas heterociclicas como antagonistas de receptores p2x7 | |
| AR086036A1 (es) | DERIVADOS DE ETINILO COMO MODULADORES ALOSTERICOS POSITIVOS DE (mGluR5) | |
| AR083492A1 (es) | Derivados aminicos para el tratamiento de trastornos proliferativos de la piel | |
| ECSP13012990A (es) | Derivados de pirazolidin-3-ona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |